Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-α-acetylmethadol, and paclitaxel

American Journal of Perinatology

Volumn 23, Issue 7, 2006, Pages 423-430

  Nekhayeva, Ilona A ^a   Nanovskaya, Tatiana N ^b   Hankins, Gary D V ^b   Ahmed, Mahmoud S ^b  

^a BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Buprenorphine; Human placenta; Levo acetylmethadol; P glycoprotein

Indexed keywords

BUPRENORPHINE; ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LEVACETYLMETHADOL; OPIATE; PACLITAXEL; PLACENTA PROTEIN;

ARTICLE; CLEARANCE INDEX; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSPORT; FETAL TRANSFER RATE; FETOPLACENTAL UNIT; HUMAN; HUMAN CELL; HUMAN TISSUE; MATERNAL CLEARANCE; OPIATE ADDICTION; PERFUSION PRESSURE; PLACENTAL TRANSFER; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ACRIDINES; ANALGESICS, OPIOID; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BUPRENORPHINE; FEMALE; FETUS; HUMANS; METHADYL ACETATE; P-GLYCOPROTEIN; PACLITAXEL; PLACENTA; TETRAHYDROISOQUINOLINES;

EID: 33750317876     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951301     Document Type: Article

References (27)

1. Rosen TS, Pippenger CE. Disposition of methadone and its relationship to severity of withdrawal in the newborn. Addictive diseases. Int J 1975;2:169-178
2. Kandall SR, Albin S, Gartner LM, Lee K, Eidelman A, Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977;1:159-169
3. Brown HL, Britton KA, Mahaffey D, Brizendine E, Hiett AK, Turnquest MA. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol 1998;179:459-463
4. Fischer G, Johnson RE, Eder H, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000;95:239-244
5. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79:1-10
6. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343:1290-1297
7. Walsh SL, Johnson RE, Cone EJ, Bigelow GE. Intravenous and oral 1-alpha-acetylmethadol: pharmacodynamics and pharmacokinetics in humans. J Pharmacol Exp Ther 1998;285: 71-82
8. Nanovskaya T, Deshmukh S, Brooks M, Ahmed M. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 2002;300:26-33
9. Nanovskaya TN, Deshmukh SV, Miles R, Burmaster S, Ahmed MS. Transfer of L-alpha-acetylmethadol (LAAM) and L-alpha-acetyl-N-normethadol (norLAAM) by the perfused human placental lobule. J Pharmacol Exp Ther 2003;306:205-212
10. Nekhayeva IA, Nanovskaya TN, Deshmukh SV, Zharikova OL, Hankins GD, Ahmed MS. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol 2005; 69:187-197
11. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70:S87-S101
12. Young AM, Allen CE, Audus KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003;55:125-132
13. Nakamura Y, Ikeda S, Furukawa T, et al. Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun 1997;235:849-853
14. Ushigome F, Takanaga H, Matsuo H, et al. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur J Pharmacol 2000; 408:1-10
15. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29
16. Nanovskaya T, Nekhayeva I, Karunaratne N, Audus K, Hankins GD, Ahmed MS. Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol 2005; 69:1869-1878
17. Miller RK, Wier PJ, Maulik D, Di Sant'Agnese PA. Human placenta in vitro: Characterization during 12 h of dual perfusion. Contrib Gynecol Obstet 1985;13:77-84
18. Traunecker HC, Stevens MC, Kerr DJ, Ferry DR. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells. Br J Cancer 1999;81:942-951
19. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003; 3:1-19
20. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-959
21. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000;58:624-632
22. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267:24248-24252
23. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 1999;259:841-850
24. Schneider H. Techniques: in vitro perfusion of human placenta. In: Sastry BV, ed. Placental Toxicology. Boca Raton, FL: CRC Press; 1995:1-26
25. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478
26. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-1143
27. de Bruin NM, Ellenbroek BA, Cools AR, Coenen AM, van Luijtelaar EL. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology (Berl) 1999;142:9-17